A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.

Condition:   Asthma
Interventions:   Drug: Olodaterol (BI 1744);   Drug: Olodaterol (BI 1744);   Drug: Olodaterol (BI 1744) low;   Drug: Olodaterol (BI 1744) high;   Drug: Formoterol 12 mcg;   Drug: Placebo
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting – verified September 2010

View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days

Leave a Reply

Your email address will not be published. Required fields are marked *